(EMH.V) May 24, 2019 – Emerald Health Therapeutics Inc. has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the U.S. Food and Drug Administration (FDA) regarding policy pertaining to CBD-containing products and associated cross-border trade. The FDA is slated to begin public consultation on May 31 to discuss potential pathways for CBD products to come to market in the U.S.

“Emerald Health Therapeutics is one of Canada’s original licenced producers and has expertise on CBD extraction and associated regulatory development,” said ATACH president Michael Bronstein. “We look forward to leveraging Emerald’s knowledge and experience as we participate in the FDA process on how to best navigate and implement a potentially-new regime for products containing cannabinoids in the United States.”

“We are pleased to be asked to lead ATACH’s International Affairs Council on CBD and Hemp,” said Emerald president and executive chairman Dr. Avtar Dhillon. “We believe there is significant therapeutic and economic potential for CBD-related products generally and in the U.S., and we are eager to play a positive role in this policy formation process.”

Allan Rewak, vice-president of communications and stakeholder relations of Emerald, has been appointed as the company’s formal representative to ATACH and will utilize his experience in the Canadian cannabis legalization process to support the development of a reasonable and effective regulatory regime for CBD in the United States.

Emerald produces and sells its SYNC 25 CBD oil in the adult-use market and other high-CBD products in the medical market in Canada, and has sourced hemp to produce allowable oils in the current Canadian legal framework. It is also employing advanced formulation and delivery technology with the goal to offer customers new product choices in conjunction with new Canadian legislation that is expected to allow a broader set of ingestible and topical products in the fall of 2019 and beyond.

The American Trade Association for Cannabis and Hemp is a 501(c)(6) trade organization registered in Washington, D.C., founded to promote the expansion, protection, and preservation of businesses engaged in the legal trade of industrial, medical, and recreational cannabis and hemp-based products.

ATACH is a place for marijuana and hemp industry leaders and well­ known, well­ capitalized businesses who are entering the industry to promote marketplace expansion, develop regulation, and adopt industry standards.

ATACH is ushering in the next phase of marketplace expansion by providing a bridge from the cannabis industry to mainstream name-brand businesses who will be partners in advancing the industry and ending prohibition. The organization is playing a leading role in professionalizing industry representation and facilitating the next generation of the marketplace.

Emerald Health Therapeutics is a Canadian licensed producer of cannabis. Its 50-percent-owned Pure Sunfarms joint venture in B.C. is licensed and fully planted in the first of its two 102,193-square-metre (1.1-million-square-foot) greenhouses. The capacity of each greenhouse is estimated to exceed 75,000 kilograms of cannabis annually.

Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products aimed at providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Leave a Reply

Your email address will not be published. Required fields are marked *